Lysergic acid diethylamide (LSD-25) and schizophrenic reactions. A comparative study
OrthoEvidence Journal (OE Journal) - ACE Report
OE Journal. 2022;10(12):12 J Nerv Ment Dis. 1968 23-Feb;():. 10.1097/00005053-196808000-00008Study Summary
Fifty healthy subjects underwent a double-blind, placebo-controlled study to compare the effects of LSD on these subjects to symptoms of schizophrenic patients. For the fifty healthy subjects, thirty received LSD while twenty received placebo. Questionnaires assessed the effects of LSD on perception, memory, imagery, and cognition. The schizophrenic patients, ten of which were paranoid and the other ten undifferentiated, also received this questionnaire. The undifferentiated schizophrenics had lower scores than the paranoid patients, but the responses did not resemble the LSD group. The responses of paranoid patients resembled the LSD group.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
Are you affiliated with one of our partner associations?
Click here to gain complimentary access as part your association member benefits!
0 of 4 monthly FREE articles unlocked
